ClinicalTrials.gg
TerminatedNCT06033833RIVER-ASTHMAUpdated Oct 2, 2026

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

A Phase 2 interventional study of Amlitelimab and Placebo in Asthma, sponsored by Sanofi. Terminated at 68 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision; the decision is not related to any safety concern.
Updated Oct 2, 2026Now TerminatedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
335
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.

Enrollment
22nd of 31
335 · median 450
Started
2023
with 3 others
Phase 2
11 of 37
1 open now
Registered
31st of 37
by date

Among the 37 studies in Asthma by Sanofi, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2023, is one of 11 in phase 2, and was the 31st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Asthma by Sanofi, or all of them as a file.
02

Study summary

This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each participant will receive open-label amlitelimab from Week 24 onwards. The purpose of this study is to evaluate long-term safety, tolerability, and efficacy of amlitelimab for the treatment of adult participants with moderate-to-severe asthma who have previously been enrolled and completed the treatment period of the parent study. The study duration will be up to 156 weeks. The treatment duration will be up to 144 weeks. The number of visits will be 18.

Read the detailed description

The duration of the study for each participant will be up to 156 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderate-to-severe asthma who completed the treatment period of the parent study per protocol
  • Participants on background dose with medium-to-high doses of ICS therapy (≥500 µg of fluticasone propionate daily or comparable ICS dosage up to a maximum of 2000 µg/day of fluticasone propionate or clinically comparable) in combination with a second or third controller (eg, LABA, LTRA, LAMA, methylxanthines), with or without OCS (up to a maximum of 15 mg prednisone or equivalent daily or 30 mg every other day) as maintained during the parent study in which they participated Note for Japan: participants must be on ≥400 μg of fluticasone propionate daily or equivalent.
  • for male and female participants;

For female participants:

  • incapable of becoming pregnant
  • not pregnant or breast feeding
  • not to donate or cryopreserve eggs for female participants For male participants
  • No sperm donation or cryopreserving sperms

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Chronic lung disease other than asthma
  • Participants who developed a new medical condition or a change in status of an established medical condition or require a new treatment or medication prior to enrollment, which (per Investigator's medical judgment) would adversely affect the participation in this study or would require permanent IMP discontinuation
  • Current smoker or active vaping of any products and/or marijuana smoking
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • Any new development with the participant's disease or condition or any significant laboratory test abnormality during the parent study that, in the opinion of the Investigator, may present an unreasonable risk for the participant
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
  • Participants are employees of the investigative site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    Treatment group 1

    Subcutaneous Injection as per protocol

    Drug: Amlitelimab

  • Experimental
    Treatment group 2

    Subcutaneous injection as per protocol

    Drug: Placebo

Interventions

  • Injection Solution: by subcutaneous injection (SCI)

  • DrugPlacebo

    Injection Solution: by subcutaneous injection (SCI)

06

What researchers measure

Primary outcomes

  1. Percentage of participants with treatment-emergent adverse events

    Percentage of participants with treatment emergent Adverse Events.

    Time frame: From baseline up to Week 156 (EOS of LTS17510)

Secondary outcomes

  1. Percentage of participants who experienced adverse events.

    Data reported for participants who experienced adverse events of special interest (AESI) and serious adverse events (SAEs).

    Time frame: From baseline up to Week 156 (End of Study [EOS] of LTS17510)

  2. Annualized rate of severe exacerbation events over treatment period from parent study baseline

    Severe exacerbation events over treatment period from parent study baseline are defined as: Worsening of asthma requiring the use of systemic corticosteroids for ≥3 days (or a single IM or IV injection of corticosteroids) or, in the case of a stable maintenance regimen of oral corticosteroids for the treatment of asthma, a doubling of the dose for 3 or more days; or Hospitalization or emergency room visit or urgent care visit because of asthma, requiring systemic corticosteroids.

    Time frame: From baseline of the parent study up to Week 144 (End of Treatment [EOT] of LTS17510)

  3. Annualized rate of severe exacerbation events over treatment period from LTS17510 study baseline

    Severe exacerbation events over treatment period from LTS17510 study baseline defined as: Worsening of asthma requiring the use of systemic corticosteroids for ≥3 days (or a single IM or IV injection of corticosteroids) or, in the case of a stable maintenance regimen of oral corticosteroids for the treatment of asthma, a doubling of the dose for 3 or more days; or Hospitalization or emergency room visit or urgent care visit because of asthma, requiring systemic corticosteroids.

    Time frame: From baseline of the LTS17510 study Up to Week 144 (EOT of LTS17510)

  4. Time to first exacerbation event from LTS17510 study baseline

    Time frame: From baseline of the LTS17510 study Up to Week 144 (EOT of LTS17510)

  5. Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit over treatment period from parent study baseline

    Severe asthma exacerbations are defined as: Worsening of asthma requiring the use of systemic corticosteroids for ≥3 days (or a single IM or IV injection of corticosteroids) or, in the case of a stable maintenance regimen of oral corticosteroids for the treatment of asthma, a doubling of the dose for 3 or more days; or Hospitalization or emergency room visit or urgent care visit because of asthma, requiring systemic corticosteroids.

    Time frame: From baseline of the parent study up to Week 144 (EOT of LTS17510)

  6. Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit over treatment period from LTS17510 study baseline

    Severe asthma exacerbations are defined as: Worsening of asthma requiring the use of systemic corticosteroids for ≥3 days (or a single IM or IV injection of corticosteroids) or, in the case of a stable maintenance regimen of oral corticosteroids for the treatment of asthma, a doubling of the dose for 3 or more days; or Hospitalization or emergency room visit or urgent care visit because of asthma, requiring systemic corticosteroids.

    Time frame: From baseline of the LTS17510 study up to Week 144 (EOT of LTS17510)

  7. Change from parent study baseline in prebronchodilator (BD) and post-BD forced expiratory volume in 1 second (FEV1) at each spirometry endpoint

    Time frame: From baseline of parent study up to week 144 (EOT of LTS17510)

  8. Change from LTS17510 study baseline in pre bronchodilator (BD) and post-BD forced expiratory volume in 1 second (FEV1) at each spirometry endpoint

    Time frame: From baseline of LTS17510 study up to week 144 (EOT of LTS17510)

  9. Change from parent study baseline in pre-BD and post-BD peak expiratory flow [PEF] at each spirometry endpoint

    Time frame: From baseline of parent study up to Week 144 (EOT of LTS17510)

  10. Change from LTS17510 study baseline in pre-BD and post-BD peak expiratory flow [PEF] at each spirometry endpoint

    Time frame: From baseline of LTS17510 study up to Week 144 (EOT of LTS17510)

  11. Change from parent study baseline in Pre-BD and post-BD forced vital capacity [FVC] at each spirometry endpoint

    Time frame: From baseline of parent study up to Week 144 (EOT of LTS17510)

  12. Change from LTS17510 study Baseline in Pre-BD and post-BD forced vital capacity [FVC] at each spirometry endpoint

    Time frame: From baseline of lTS17510 study up to Week 144 (EOT of LTS17510)

  13. Change from parent study baseline in pre-BD and post-BD forced expiratory flow [FEF] 25% to 75%) at each spirometry endpoint

    Time frame: From baseline of parent study up to Week 144 (EOT of LTS17510)

  14. Change from LTS17510 study baseline in pre-BD and post-BD forced expiratory flow [FEF] 25% to 75%) at each spirometry endpoint

    Time frame: From baseline of LTS17510 study up to Week 144 (EOT of LTS17510)

  15. Change from parent study baseline in Asthma Control Questionnaire (ACQ)-5, ACQ-6, and ACQ-7 scores

    The ACQ is a validated questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. Each item of the ACQ is measured on a 7-point response scale (0=no impairment, 6=maximum impairment). The ACQ score is the mean of the item responses and ranges from 0 (totally controlled) and 6 (severely uncontrolled).

    Time frame: From parent study baseline up to Week 144 (EOT of LTS17510)

  16. Change from LTS17510 study baseline in Asthma Control Questionnaire (ACQ)-5, ACQ-6, and ACQ-7 scores

    The ACQ is a validated questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. Each item of the ACQ is measured on a 7-point response scale (0=no impairment, 6=maximum impairment). The ACQ score is the mean of the item responses and ranges from 0 (totally controlled) and 6 (severely uncontrolled).

    Time frame: From LTS17510 study baseline up to Week 144 (EOT of LTS17510)

  17. Change from parent study baseline in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: From parent study baseline up to Week 144 (EOT of LTS17510)

  18. Change from LTS17510 study baseline in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: From LTS17510 study baseline up to Week 144 (EOT of LTS17510)

  19. Serum amlitelimab concentrations

    Time frame: From baseline up to Week156 (EOS of LTS17510)

  20. Incidence of anti- amlitelimab antibody positive response

    Time frame: From baseline up to Week 156 (EOS of LTS17510)

  21. Change from parent study baseline and from LTS17510 in Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ [S]) Self-Administered Score

    The AQLQ(S) was designed as a self-administered participant reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma over the past two weeks. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7.

    Time frame: From baseline up to Weeks 144 (EOT of LTS17510)

07

Study locations

68 sites
  • Bensch Research Associates- Site Number : 8400004
    Stockton, California 95207, United States
  • Helix Biomedics- Site Number : 8400029
    Boynton Beach, Florida 33435, United States
  • Savin Medical Group - Miami Lakes- Site Number : 8400015
    Miami Lakes, Florida 33014, United States
  • Pines Care Research Center- Site Number : 8400028
    Pembroke Pines, Florida 33025, United States
  • Treasure Valley Medical Research- Site Number : 8400031
    Boise, Idaho 83706, United States
  • Johns Hopkins Bayview Medical Center- Site Number : 8400012
    Baltimore, Maryland 21224, United States
  • OK Clinical Research- Site Number : 8400001
    Edmond, Oklahoma 73034, United States
  • South Texas Medical Research Institute - TTS Research- Site Number : 8400011
    Boerne, Texas 78006, United States
  • Investigational Site Number : 0320008
    La Plata, Buenos Aires 1900, Argentina
  • Investigational Site Number : 0320005
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320006
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320009
    Buenos Aires, 1650, Argentina
  • Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760002
    Vitória, Espírito Santo 29055-450, Brazil
  • Associacao Proar- Site Number : 0760004
    Salvador, Estado de Bahia 40060-330, Brazil
  • Instituto Méderi de Pesquisa e Saúde- Site Number : 0760001
    Passo Fundo, Rio Grande do Sul 99010-170, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760007
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Clinica de Alergia Martti Antila- Site Number : 0760003
    Sorocaba, São Paulo 18040-425, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760008
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1240008
    Ottawa, Ontario K1G 6C6, Canada
  • Investigational Site Number : 1240007
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Investigational Site Number : 1520006
    Talca, Maule Region 3465584, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 7750495, Chile
  • Investigational Site Number : 1520008
    Santiago, Reg Metropolitana de Santiago 8380465, Chile
  • Investigational Site Number : 1520005
    Quillota, Valparaiso 2260877, Chile
  • Investigational Site Number : 3480009
    Edelény, 3780, Hungary
  • Investigational Site Number : 3480011
    Gödöllő, 2100, Hungary
  • Investigational Site Number : 3480006
    Püspökladány, 4150, Hungary
  • Investigational Site Number : 3480012
    Százhalombatta, 2440, Hungary
  • Investigational Site Number : 3800004
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800003
    Rome, Roma 00168, Italy
  • Investigational Site Number : 3800001
    Verona, 37134, Italy
  • Investigational Site Number : 3920010
    Sakai, Osaka 591-8555, Japan
  • Investigational Site Number : 3920004
    Chūō, Tokyo 104-0031, Japan
  • Investigational Site Number : 3920019
    Hiroshima, 732-0052, Japan
  • Investigational Site Number : 3920005
    Tokyo, 103-0027, Japan
  • Investigational Site Number : 3920001
    Tokyo, 140-8522, Japan
  • Investigational Site Number : 4840001
    Guadalajara, Jalisco 44100, Mexico
  • Investigational Site Number : 4840005
    Guadalajara, Jalisco 44670, Mexico
  • Investigational Site Number : 4840008
    Mérida, Yucatán 97070, Mexico
  • Investigational Site Number : 4840002
    Chihuahua City, 31000, Mexico
  • Investigational Site Number : 6160001
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Investigational Site Number : 6160006
    Krakow, Lesser Poland Voivodeship 31-209, Poland
  • Investigational Site Number : 6160007
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • Investigational Site Number : 6160004
    Bialystok, Podlaskie Voivodeship 15-044, Poland
  • Investigational Site Number : 6160002
    Gdansk, Pomeranian Voivodeship 80-405, Poland
  • Investigational Site Number : 6160003
    Elblag, 82-300, Poland
  • Investigational Site Number : 7100007
    Benoni, 1500, South Africa
  • Investigational Site Number : 7100002
    Cape Town, 7530, South Africa
  • Investigational Site Number : 7100001
    Cape Town, 7700, South Africa
  • Investigational Site Number : 7100004
    Middelburg, 1055, South Africa
  • Investigational Site Number : 4100004
    Daegu, Gyeongsangbuk-do 42415, South Korea
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number : 4100005
    Seoul, Seoul-teukbyeolsi 05030, South Korea
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 05505, South Korea
  • Investigational Site Number : 4100006
    Seoul, Seoul-teukbyeolsi 06591, South Korea
  • Investigational Site Number : 7920001
    Istanbul, 34098, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    Izmir, 35100, Turkey (Türkiye)
  • Investigational Site Number : 7920005
    İzmit, 41001, Turkey (Türkiye)
  • Investigational Site Number : 7920008
    Kayseri, 38039, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    Mersin, 33070, Turkey (Türkiye)
  • Investigational Site Number : 8260001
    Bradford, BD9 6RJ, United Kingdom
08

References and documents

Publications

  • Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025 Jan;134(1):9-18. doi: 10.1016/j.anai.2024.09.016. Epub 2024 Oct 10. PubMed 39393433 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Sep 2026, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2023
First posted
Sep 13, 2023
StartActual
Sep 5, 2023
Primary completionActual
Sep 22, 2026
CompletionActual
Sep 22, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Sponsor decision; the decision is not related to any safety concern.
changed Oct 2, 2026
Primary completion
Sep 29, 2026→Sep 22, 2026 (actual)
Oct 2, 2026
Study completion
Sep 29, 2026→Sep 22, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Terminated
    Why stopped Sponsor decision; the decision is not related to any safety concern.
    Primary completion Sep 29, 2026→Sep 22, 2026 (now actual)
    Study completion Sep 29, 2026→Sep 22, 2026 (now actual)
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06033833
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Sep 5, 2023
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Oct 2, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion